en · de · es · fr · pt
hplc-notes.peptides6088.com › Info › Tb-500 Identity And Naming Background — Reference Sheet

Tb-500 Identity And Naming Background — Reference Sheet

By Editorial Desk · published 2025-09-18 · last reviewed 2025-11-06 · Info

thymosin beta-4 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-11-06. Numbers and descriptions here follow the published literature rather than marketing material.

TB-500 Identity and Naming Background

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Identification and Molecular Background

Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.

Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.

TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.

Tb-500 at a glance

PropertyValueNotes
Name typeCommercial trade nameNot a systematic chemical identifier
Parent peptideThymosin beta-443-residue natural peptide
Common fragment sequenceLKKTETQMaps to part of the actin-binding region
Molecular size classRoughly 0.8-1.0 kDaDepends on exact fragment and terminal modification
Regulatory statusProhibited in sportGrouped with peptide hormones in many frameworks

Handling, Storage, and Analysis

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.

Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.

Related pages on this site

Thymosin Beta-4 Fragment Identity

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Thymosin Beta-4 Fragment Background

Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.

Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.

TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.

Handling, Stability and Analytical Detection

Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.

Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.

Reference notes

He played the next three weeks in the Victorian Football League (VFL) for Essendon's affiliate team, the Bendigo Bombers, before returning to the senior side in round twenty for the ninety-eight-point loss against Collingwood at the Melbourne Cricket Ground and he played the remainder of the year to finish with fourteen matches for the season. Despite being drafted as a midfielder, he played the majority of the season on the half-back flank and struggled for continuity as he played no more than four matches consecutively at a time. Incoming coach, James Hird earmarked a greater role in the midfield for Melksham during the 2011 season and he performed strongly in the midfield during the 2011 NAB Cup with The Age reporter, Michael Gleeson noting Melksham would have a bigger impact on the field in 2011 compared to his debut year. He went on to play every match during the season and was praised for his performances in the midfield by many in the industry, some of which were former player, Garry Lyon, and journalists, Ashley Porter and Martin Blake. In round fifteen, he kicked the match-winning goal in Essendon's four-point win against the previously undefeated Geelong at Etihad Stadium and was named best on ground, earning three Brownlow votes for the first time in his career. He played his first final in the sixty-two-point loss against Carlton in the first elimination final at the Melbourne Cricket Ground. At the end of the season he was noted as an emerging leader of the club by Herald Sun journalist, Sam Edmund.

==== History of opium production ==== Despite the social and cultural costs, communities in Guerrero such as La Sierra and La Montaña have continuously relied on the illegal opiate market as their primary source of income. Historical dispossession in Guerrero has weakened economic stability in under-developed regions including Atoyac de Álvarez and Ayutla de los Libres.

Saint Paul Public Schools Solid phase peptide synthesis Solution precursor plasma spray Steam Powered Preservation Society South Park Primary School, a primary school in London, United Kingdom Scandinavian Plant Physiology Society Social Psychological and Personality Science, a quarterly academic journal for social and personality psychology-related topics Spectral Parameter Power Series, a method for solving Sturm–Liouville equations Super Proton-Antiproton Collider (SppS), a modification of the Super Proton Synchrotron, an accelerator at CERN

Collins described her return to the show as "redemption" after withdrawing from her original series, comparing herself to Lara Croft and noted that although the series was tougher this time around, she felt she had "unfinished business" and ultimately "shut it down". She entered camp on the second day of the series alongside Craig Charles, who had also appeared on her original series. Collins completed a helicopter ride into camp, before she and Charles took part in an eating trial, which was won by the latter. She resided in the basic camp "Savannah Scrub" alongside Adam Thomas, Beverley Callard and Seann Walsh for several days, until they joined the main camp after completing a trial in which they were situated in water tanks and had to transport keys to one another. Following her arrival in main camp, Collins fell out of her hammock during one of the episodes. She completed her third trial alongside Scarlett Moffatt, during which time the camp was split into teams. She ultimately lost this trial; however her team the "Rhinos" were victorious and ultimately won a banquet and a trip on safari. Following a safety chain elimination in which Collins was saved by Jimmy Bullard and David Haye was eliminated, Haye then had to choose another campmate to leave alongside him. He chose Collins, who ultimately became the third campmate to be eliminated from the series after spending nine days in camp. Later in the year, Collins is set to begin starring in a Sky One reality series, Gemma Collins: Everything.

Sources: en.wikipedia.org

Reference notes

Biden did not support national same-sex marriage rights while in the Senate and voted for the Defense of Marriage Act, but opposed proposals for constitutional amendments that would have banned same-sex marriage nationwide. Biden has supported same-sex marriage since 2012. As a senator, Biden forged deep relationships with police groups and was a chief proponent of a Law Enforcement Officers' Bill of Rights measure that police unions supported but police chiefs opposed. In 2020, Biden also ran on decriminalizing cannabis, after advocating harsher penalties for drug use as a senator. Biden believes action must be taken on climate change. As a senator, he co-sponsored the Boxer–Sanders Global Warming Pollution Reduction Act, the most stringent climate bill in the United States Senate. Biden supports nature conservation. According to a report from the Center for American Progress, he broke several records in this domain. He took steps to protect old-growth forests. Biden opposes drilling for oil in the Arctic National Wildlife Refuge. He wants to achieve a carbon-free power sector in the U.S. by 2035 and stop emissions completely by 2050. His program included reentering the Paris Agreement, green building and more. Biden supports environmental justice, including climate justice and ocean justice. Biden called global temperature rise above the 1.5°C limit the "only existential threat humanity faces even more frightening than a nuclear war".

Anticholinergic side-effects (common for olanzapine, clozapine; less likely on risperidone) such as: Blurred vision Constipation Dry mouth (although hypersalivation may also occur) Reduced perspiration Cognitive decline and memory impairment Tardive dyskinesia appears to be more frequent with high-potency first-generation antipsychotics, such as haloperidol, and tends to appear after chronic and not acute treatment. It is characterized by slow (hence the tardive) repetitive, involuntary and purposeless movements, most often of the face, lips, legs, or torso, which tend to resist treatment and are frequently irreversible. The rate of appearance of TD is about 5% per year of use of antipsychotic drug (whatever the drug used) Breast cancer: a systematic review and meta-analysis of observational studies with over 2 million individuals estimated an association between antipsychotic use and breast cancer by over 30%. Rare/Uncommon (<1% incidence for most antipsychotic drugs) adverse effects of antipsychotics include:

In the minor reaction pathway, a Prilezhaev epoxidation results in the formation of thiophene-2,3-epoxide that rapidly rearranges to the isomer thiophene-2-one. Trapping experiments demonstrate that this pathway is not a side reaction from the S-oxide intermediate, while isotopic labeling with deuterium confirm that a 1,2-hydride shift occurs and thus that a cationic intermediate is involved. If the reaction mixture is not anhydrous, this minor reaction pathway is suppressed as water acts as a competing base. Oxidation may be relevant to the metabolic activation of various thiophene-containing drugs, such as tienilic acid and the investigational anticancer drug OSI-930.

== Activity and Specificity == In common with most enzymes in family C1, caricain accepts hydrophobic amino acid residues in both S2 and S3. However, other residues are also accommodated in these subsites, including proline in S2, and lysine in S3. The specificities of three cysteine endopeptidases from papaya latex were found to be very similar. Caricain and chymopapain appeared to prefer an aliphatic to a hydrophobic residue at P2. The similarity in specificity of caricain and chymopapain was demonstrated by the fact that, of 44 peptide bonds in manatee hemoglobin cleaved by caricain, 29 were also cleaved by chymopapain. An earlier study had highlighted the similarity in specificity of caricain, chymopapain and papain. All seven bonds of the oxidized B chain of insulin that were hydrolyzed by caricain were also cleaved by papain, and six were hydrolyzed by chymopapain. Caricain can be assayed with Bz-ArgkNHPhNO2, kcat/Km being 187 M21 s21 at pH 6.8 and 40˚C. More sensitive substrates may employ a fluorometric leaving group, kcat/Km for the hydrolysis of Z-Phe-ArgkNHMec being 1.06 3 106 M21 s21 (pH 6.8, 40˚C). The enzyme exhibits a broad pH-activity profile, with the optimum near 7.0. About half-maximal activity is still achieved at pH values of about 5.3 and 8.3, and the profile is reported to be governed by at least three ionizing groups. The active-site sulfur requires reduction for catalytic competence, and this is best achieved by the inclusion of low millimolar concentrations of cysteine in assay buffers.

=== Burn pits === A form of BO is starting to present in Iraq and Afghanistan veterans. It has been attributed to veterans being exposed to trash burn pits. Veterans present with shortness of breath and other asthma-like symptoms. The only way to diagnose this condition is by doing a lung biopsy as chest X-rays and CT scans come back as normal. The US government still denies that there is any correlation between burn pits and health problems, but has started an "Airborne Hazards and Open Burn Pit Registry" to begin tracking the health of veterans who were exposed to burn pits to see if there is a connection.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.

What does research on the fragment actually measure?

Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.

Why does the name cause confusion?

Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.

What is TB-500 chemically?

It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.

Network